Skip to main
NBIX
NBIX logo

Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences (NBIX) Analyst Ratings

Based on 33 analyst ratings
Buy
Strong Buy 39%
Buy 42%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Neurocrine Biosciences is poised for long-term growth driven by increasing patient diagnoses, particularly in classic congenital adrenal hyperplasia (CAH), where the patient population has grown by 3,000 since 2018, reflecting heightened demand for its therapies. The company reported a non-GAAP net earnings per share of approximately $1.69 for 4Q23, indicating resilience despite competitive pressures, with management expressing confidence in the continued market expansion of INGREZZA given that a significant majority of tardive dyskinesia patients remain untreated. Furthermore, the anticipated pivotal programs and ongoing research initiatives in major depressive disorder and schizophrenia suggest a robust pipeline that could enhance the company's growth trajectory in the coming years.

Bears say

Neurocrine Biosciences faces a negative outlook primarily attributed to its lowered sales guidance for Ingrezza in FY25, projected at $2.5-2.6 billion, which reflects anticipated challenges in market dynamics, including competitive pressures and stricter payer management. In addition, recent sales figures for Ingrezza were disappointing, with 4Q24 revenues of approximately $615 million falling short of both consensus and internal estimates, indicating a deceleration in revenue growth. Furthermore, the company's overall revenue assumption for year-end 2025 was revised downwards from $2,846 million to $2,648 million, highlighting ongoing struggles to boost sales amidst a complex healthcare environment.

Neurocrine Biosciences (NBIX) has been analyzed by 33 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 42% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neurocrine Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neurocrine Biosciences (NBIX) Forecast

Analysts have given Neurocrine Biosciences (NBIX) a Buy based on their latest research and market trends.

According to 33 analysts, Neurocrine Biosciences (NBIX) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $137.52, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $137.52, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neurocrine Biosciences (NBIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.